PVLA

Palvella Therapeutics Inc

Feb 25 • 04:00PM ET

128.60

+8.19 6.80 %

Healthcare • Biotechnology • USA • NASD

Feb 25, 8:00 PMPalvella Therapeutics prices upsized $200 million common stock offering at $125 per share

Peers: SRPT AGEN ADAP BLUE KURA FATE MRNA NVAX CRSP SGMO

| Held by: XBI VTI IWM VXF IWO VTWO VFMO IWC DWAS VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	32.16%	Shs Outstand	11.09M	Perf Week	61.56%
Market Cap	1.52B	Forward P/E	-	EPS next Y	-3.88	Insider Trans	-0.45%	Shs Float	8.03M	Perf Month	47.85%
Enterprise Value	1.47B	PEG	-	EPS next Q	-0.91	Inst Own	75.11%	Short Float	17.06%	Perf Quarter	36.68%
Income	-	P/S	-	EPS this Y	55.07%	Inst Trans	20.23%	Short Ratio	4.70	Perf Half Y	156.53%
Sales	-	P/B	36.86	EPS next Y	-10.34%	ROA	-	Short Interest	1.37M	Perf YTD	22.86%
Book/sh	3.49	P/C	23.94	EPS next 5Y	13.97%	ROE	-	52W High	127.69 0.71%	Perf Year	565.98%
Cash/sh	5.37	P/FCF	-	EPS past 3/5Y	48.30% 29.42%	ROIC	-	52W Low	18.23 605.62%	Perf 3Y	15.65%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.59% 8.32%	Perf 5Y	-42.59%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	54.84%	Oper. Margin	-	ATR (14)	8.91	Perf 10Y	-3.16%
Dividend Ex-Date	-	Quick Ratio	6.49	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	77.32	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.49	EPS Q/Q	62.90%	SMA20	50.95%	Beta	-0.22	Target Price	222.75
Payout	-	Debt/Eq	0.41	Sales Q/Q	-	SMA50	39.07%	Rel Volume	2.03	Prev Close	120.41
Employees	14	LT Debt/Eq	0.41	Earnings	Nov 11 BMO	SMA200	106.53%	Avg Volume	291.26K	Price	128.60
IPO	Jan 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-22.87% -	Trades		Volume	580,680	Change	6.80%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Initiated	Mizuho	Outperform	$205
Dec-05-25	Initiated	BTIG Research	Buy	$167
Dec-04-25	Initiated	Craig Hallum	Buy	$175
Nov-19-25	Upgrade	Raymond James	Outperform → Strong Buy	$143
Sep-09-25	Initiated	Oppenheimer	Outperform	$85
Aug-06-25	Initiated	Raymond James	Outperform	$54
Jul-21-25	Initiated	Truist	Buy	$56
Apr-09-25	Initiated	Chardan Capital Markets	Buy	$50
Mar-26-25	Initiated	Stifel	Buy	$45
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$50
Feb-20-25	Initiated	Canaccord Genuity	Buy	$39
Feb-05-25	Initiated	TD Cowen	Buy	$44
Dec-26-24	Initiated	H.C. Wainwright	Buy	$38
Dec-18-24	Initiated	Cantor Fitzgerald	Overweight
Mar-13-20	Upgrade	Robert W. Baird	Neutral → Outperform	$5
Jul-30-19	Downgrade	Robert W. Baird	Outperform → Neutral
May-14-19	Initiated	Robert W. Baird	Outperform	$5
Mar-19-18	Initiated	Jefferies	Buy	$12
Mar-19-18	Initiated	Evercore ISI	Outperform	$13
Jan-16-18	Reiterated	H.C. Wainwright	Buy	$9 → $12

Show Previous Ratings

Feb-25-26 07:57PM	Palvella Therapeutics Announces Pricing of Upsized Public Offering (GlobeNewswire) +6.80%
10:10AM	Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright (TipRanks)
Feb-24-26 08:07PM	Palvella Therapeutics Shares Jump as Phase 3 SELVA Trial Hits Primary Endpoint for QTORIN Rapamycin (MarketBeat) +37.08%
04:08PM	Why Top 2% Palvella Therapeutics, Up 33%, Just Blew Past Its 50-Day Line (Investor's Business Daily)
04:05PM	Palvella Therapeutics Announces Proposed Public Offering (GlobeNewswire)
11:10AM	Loading…
11:10AM	Stocks Rally as AI-Fueled Worries Ease (Barchart)
10:15AM	Palvella Therapeutics (PVLA) Surges On Positive Phase 3 QTORIN SELVA Data (Benzinga)
09:59AM	Stocks Rebound as Software Stocks Recover (Barchart)
09:32AM	Why Top 2% Palvella Therapeutics Is About To Blow Past Its 50-Day Line (Investor's Business Daily)
06:30AM	Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic Malformations (GlobeNewswire)
06:00AM	Novo to cut GLP-1 drug prices; Palvella soars on study data (BioPharma Dive)
Feb-23-26 05:00PM	Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic Malformations (GlobeNewswire)
Feb-02-26 07:30AM	Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis (GlobeNewswire)
Jan-09-26 07:30AM	Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies (GlobeNewswire) -5.10%
Jan-07-26 09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly) +11.72%
07:30AM	Loading…
07:30AM	Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs (GlobeNewswire)
Dec-21-25 07:31AM	High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin (Insider Monkey)
Dec-16-25 10:40AM	Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer (TipRanks) +8.80%
07:30AM	Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Angiokeratomas (GlobeNewswire)
Dec-15-25 06:00AM	Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies (GlobeNewswire) -9.74%
Nov-24-25 11:05AM	The Short-Sellers May Be Right About This Red-Hot Pharma Stock (Barchart)
Nov-11-25 04:01PM	Palvella Therapeutics Inc (PVLA) Q3 2025 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
07:37AM	Palvella Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-25 07:30AM	Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference (GlobeNewswire)
Nov-05-25 06:00AM	Palvella Therapeutics Announces New QTORIN Product Candidate, QTORIN Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies (GlobeNewswire)
Nov-04-25 07:30AM	Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025 (GlobeNewswire)
Oct-13-25 07:30AM	U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations (GlobeNewswire) +9.04%
Sep-24-25 06:00AM	Palvella Therapeutics Announces Expansion of QTORIN Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies (GlobeNewswire)
Sep-17-25 07:30AM	Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy (GlobeNewswire)
07:30AM	Loading…
Sep-15-25 07:30AM	Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN Rapamycin for Cutaneous Venous Malformations (GlobeNewswire)
Sep-03-25 07:30AM	Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer (GlobeNewswire)
Aug-28-25 07:30AM	Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire) -9.12%
Aug-14-25 07:35AM	Palvella Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-25 07:30AM	Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025 (GlobeNewswire)
Aug-06-25 09:36AM	Snap downgraded, Leidos upgraded: Wall Street's top analyst calls (The Fly)
Aug-05-25 07:30AM	Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Jul-09-25 07:20AM	Palvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN Rapamycin (Insider Monkey)
Jun-30-25 07:30AM	Palvella Therapeutics Added to Russell 3000 and Russell 2000 Indexes (GlobeNewswire)
Jun-23-25 07:30AM	Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% (GlobeNewswire)
Jun-18-25 07:30AM	Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors (GlobeNewswire)
Jun-09-25 07:30AM	Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations (GlobeNewswire)
May-27-25 08:00AM	Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer (GlobeNewswire)
May-16-25 03:09AM	Palvella Therapeutics Inc (PVLA) Q1 2025 Earnings Call Highlights: Strong Clinical Progress ... (GuruFocus.com)
May-15-25 07:30AM	Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-25 07:30AM	Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 (GlobeNewswire)
May-05-25 07:30AM	Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025 (GlobeNewswire)
Apr-30-25 05:44AM	Why Palvella Therapeutics, Inc. (PVLA) is Surging in 2025 (Insider Monkey)
Apr-23-25 04:15PM	Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology (GlobeNewswire)
Apr-22-25 07:30AM	Palvella Therapeutics Granted Additional U.S. Patent for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations (GlobeNewswire) +5.74%
Apr-11-25 07:30AM	Palvella Therapeutics Announces QTORIN Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology (GlobeNewswire) +9.51%
Apr-04-25 08:00AM	Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference (GlobeNewswire)
Apr-02-25 08:00AM	Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology (GlobeNewswire) +14.33%
Apr-01-25 12:52PM	Is Palvella Therapeutics Inc. (PVLA) the Best Performing NASDAQ Stock So Far in 2025? (Insider Monkey) -15.72%
03:01AM	Palvella Therapeutics Inc (PVLA) Q4 2024 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com)
Mar-31-25 07:30AM	Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-27-25 09:50AM	Is Palvella Therapeutics (PVLA) the Best Performing Stock So Far in 2025? (InsiderMonkey)
Mar-18-25 08:30AM	Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025 (GlobeNewswire)
Mar-01-25 05:30PM	Why Palvella Therapeutics, Inc. (PVLA) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-25-25 08:00AM	Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference (GlobeNewswire)
Feb-21-25 09:35AM	Palantir initiated, Roku upgraded: Wall Streets top analyst calls (TipRanks)
Feb-10-25 08:00AM	Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old (GlobeNewswire)
Jan-10-25 08:00AM	Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies (GlobeNewswire)
Jan-08-25 08:00AM	Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Cutaneous Venous Malformations (GlobeNewswire)
Dec-27-24 06:20AM	Palvella Therapeutics initiated with a Buy at H.C. Wainwright (TipRanks)
Nov-13-24 04:53PM	Pieris Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
Nov-07-24 08:30AM	Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Microcystic Lymphatic Malformations (GlobeNewswire)
Oct-17-24 07:30AM	Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer (GlobeNewswire)
Oct-15-24 07:30AM	Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference (GlobeNewswire)
Oct-03-24 07:30AM	Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations (GlobeNewswire)
Aug-14-24 07:11PM	Pieris Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
Jul-24-24 06:30AM	Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement (ACCESSWIRE) +88.60%
Jul-08-24 08:15AM	Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors (GlobeNewswire) -10.60%
May-17-24 02:52PM	PIRS Stock Earnings: Pieris Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace)
May-15-24 05:43PM	Pieris Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
Apr-19-24 12:10PM	Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split (ACCESSWIRE) -6.60%
Mar-27-24 08:00AM	Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential (ACCESSWIRE)
Nov-14-23 05:36PM	Pieris Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) -7.36%
Sep-25-23 12:00PM	Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why (Zacks)
Aug-24-23 12:32PM	Is Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive Analysis (GuruFocus.com)
Aug-23-23 12:00PM	Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +19.68%
Aug-17-23 08:00AM	Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific (ACCESSWIRE) +8.06%
Jul-19-23 02:02PM	Pieris lays off most staff after AstraZeneca pulls out of partnership (American City Business Journals)
08:40AM	Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises (Zacks)
Jul-18-23 01:59PM	Why Pieris Pharmaceuticals Shares Shooting Higher Today? (Benzinga) +11.81%
09:15AM	Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring (ACCESSWIRE)
Jul-17-23 07:29AM	3 Doomed Biotech Stocks Destined for Disaster (InvestorPlace)
Jun-23-23 10:50AM	Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate (Zacks) +12.02%
Jun-21-23 07:00AM	Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study (ACCESSWIRE) -70.86%
Jun-11-23 10:28AM	We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate (Simply Wall St.)
Jun-02-23 04:30PM	Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference (ACCESSWIRE) +5.35%
May-22-23 08:00AM	Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference (ACCESSWIRE) +6.00%
May-21-23 08:00AM	Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference (ACCESSWIRE)
May-15-23 06:07AM	Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
May-11-23 01:41PM	Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call Transcript (Insider Monkey) +10.60%
May-10-23 08:15AM	Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates (ACCESSWIRE)
May-05-23 06:41AM	Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shares Lagging The Industry But So Is The Business (Simply Wall St.) +7.42%
May-04-23 08:00AM	Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) (ACCESSWIRE)

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It develops a pipeline of treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded in 2015 and is headquartered in Wayne, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Goin Kathleen	Chief Operating Officer	Feb 18 '26	Option Exercise	8.11	4,302	34,883	4,302	Feb 20 04:05 PM
Goin Kathleen	Chief Operating Officer	Feb 18 '26	Sale	79.40	4,302	341,564	0	Feb 20 04:05 PM
Goin Kathleen	Officer	Feb 18 '26	Proposed Sale	80.09	4,301	344,467		Feb 18 03:59 PM
Goin Kathleen	Chief Operating Officer	Jan 21 '26	Option Exercise	8.11	4,302	34,883	4,302	Jan 23 04:05 PM
Goin Kathleen	Chief Operating Officer	Jan 21 '26	Sale	97.63	4,302	419,983	0	Jan 23 04:05 PM
Goin Kathleen	Officer	Jan 21 '26	Proposed Sale	98.01	4,302	421,639		Jan 21 04:33 PM
Goin Kathleen	Chief Operating Officer	Dec 17 '25	Option Exercise	8.11	4,302	34,883	4,302	Dec 19 04:05 PM
Goin Kathleen	Chief Operating Officer	Dec 17 '25	Sale	96.47	4,302	415,023	0	Dec 19 04:05 PM
Goin Kathleen	Officer	Dec 17 '25	Proposed Sale	96.81	4,302	416,477		Dec 17 04:33 PM
Goin Kathleen	Chief Operating Officer	Nov 19 '25	Option Exercise	8.11	4,302	34,883	4,302	Nov 21 04:25 PM
Goin Kathleen	Chief Operating Officer	Nov 19 '25	Sale	86.23	4,302	370,965	0	Nov 21 04:25 PM
Goin Kathleen	Officer	Nov 19 '25	Proposed Sale	82.94	4,302	356,808		Nov 19 04:46 PM
JENKINS GEORGE M	Director	Apr 09 '25	Buy	20.27	2,490	50,472	13,516	Apr 10 07:06 PM
JENKINS GEORGE M	Director	Apr 09 '25	Buy	20.13	2,500	50,325	183,171	Apr 10 07:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PVLA

Palvella Therapeutics Inc

Upgrade your FINVIZ experience